Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹489.45 Cr
Profit after tax
₹47.78 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations489.45+13.03%1,792.50
Other income18.92−52.71%165.18
Total income508.37+7.47%1,957.68
Employee benefit expense75.92+22.65%247.60
Finance costs46.86−9.66%205.74
Depreciation & amortisation29.98−0.60%118.12
Total expenses462.36+8.29%1,719.31
Profit before tax59.31−5.81%269.49
Tax expense11.53+3.97%39.15
Profit after tax47.78−7.90%230.34
Total comprehensive income47.78−7.21%230.23
Earnings per share
Earnings per share, basic₹0.63₹3.05
Earnings per share, diluted₹0.63₹3.05

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Fortis Healthcare reported consolidated FY26 revenue of INR9,128 crores, up 17.3%, with operating EBITDA margin expanding to 22.8% from 20.4% a year earlier. The hospital business grew 19.1% for the year while the diagnostics business under Agilus grew 8.5%, with Agilus FY26 EBITDA margin rising to 23.6% from 17.7%. Management discussed occupancy declines at some large hospitals linked to international patient softness and a government drug-price cap on oncology treatments under CGHS/ECHS schemes.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 59 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 24 Aug 2026.